Download Sample
Add to CartGlobal Opioid Induced Constipation Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Drug Class;
Mu-opioid Receptor Antagonists, Chloride Channel-2 Activators, and Others.By Prescription Type;
Over The Counter and Prescription.By End-User;
Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Opioid Induced Constipation Market (USD Million), 2021 - 2031
In the year 2024, the Global Opioid Induced Constipation Market was valued at USD 15,127.65 million. The size of this market is expected to increase to USD 105,071.52 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 31.9%.
The global opioid-induced constipation (OIC) market is experiencing significant growth as a consequence of the widespread use of opioid medications for pain management. OIC arises as a common side effect of opioid therapy, impacting patients' quality of life and treatment adherence. With the rising prescription rates of opioids globally, there has been a parallel increase in the prevalence of OIC. This surge has propelled pharmaceutical companies and researchers to develop targeted therapies aimed at alleviating constipation while maintaining the efficacy of pain management. The market is witnessing the introduction of novel pharmacological agents specifically designed to address OIC, offering patients and healthcare providers a range of treatment options to manage this distressing condition.
The evolving regulatory landscape and heightened awareness among healthcare professionals and patients are driving advancements in the OIC market. Regulatory agencies are increasingly emphasizing the need for safer and more effective treatments for opioid-related complications, including constipation. This has led to accelerated approval pathways for OIC therapies and enhanced post-marketing surveillance to monitor their safety and efficacy. Additionally, healthcare providers are actively educating patients about the potential side effects of opioid therapy, including OIC, and incorporating preventive measures and treatment strategies into pain management protocols.
The market is witnessing a surge in research and development activities focused on exploring novel therapeutic approaches and mechanisms of action for OIC management. This includes the investigation of innovative drug formulations, such as peripherally acting mu-opioid receptor antagonists (PAMORAs), which target the gastrointestinal tract to relieve constipation without affecting pain relief. Moreover, there is growing interest in complementary approaches, such as dietary modifications, behavioral interventions, and non-pharmacological therapies, to provide comprehensive care for individuals experiencing OIC. As the understanding of OIC continues to evolve and treatment options expand, the global market is poised for further growth and innovation in addressing this prevalent and burdensome condition.
Global Opioid Induced Constipation Market Recent Developments
- In November 2023, a study published in MDPI explored the use of opioid antagonists in line with dysbiosis and opioid-induced constipation in the present and future.
- In May 2022, a study published in Medical Science explored the effectiveness of itopride in the management of opioid-induced constipation among palliative care patients.
Segment Analysis
The Global Opioid Induced Constipation (OIC) Market is segmented by drug class into Mu-opioid Receptor Antagonists, Chloride Channel-2 Activators, and Others. Mu-opioid Receptor Antagonists, such as methylnaltrexone and naloxegol, are the most widely used treatment options for OIC, as they specifically target opioid receptors in the gastrointestinal tract to alleviate constipation without affecting pain relief. These drugs have become a primary choice for patients with chronic pain who are using opioids. Chloride Channel-2 Activators, including lubiprostone, work by increasing fluid secretion in the intestines, thereby improving stool passage and relieving constipation. This class of drugs is also gaining traction as an effective treatment for OIC, particularly for patients who do not respond well to other therapies. The "Others" category includes medications such as laxatives and stool softeners, which are often used in conjunction with other treatments, offering an additional layer of symptom relief.
By prescription type, the OIC market is divided into Over-The-Counter (OTC) and Prescription medications. OTC products, such as common laxatives and stool softeners, are widely available and are often the first line of defense for mild opioid-induced constipation. These medications can be accessed without a prescription and are used by a large number of patients seeking relief from mild OIC symptoms. However, for more severe or chronic cases, prescription medications are often required. Prescription treatments, such as Mu-opioid Receptor Antagonists and Chloride Channel-2 Activators, are designed for patients with more persistent OIC symptoms, particularly those on long-term opioid therapy. These drugs are typically prescribed after OTC options have proven ineffective and require medical supervision due to their targeted mechanism of action and potential side effects.
The OIC market is also segmented by end-user into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies are a significant segment, as they cater to patients who are often hospitalized for surgeries or pain management. These pharmacies provide specialized medications for managing opioid-induced constipation, ensuring that patients who require opioid pain relief also receive treatment for constipation. Retail Pharmacies play a crucial role by offering a wide range of OTC medications, including laxatives and stool softeners, and some prescription drugs to treat OIC. The accessibility of retail pharmacies ensures that patients can conveniently manage mild to moderate symptoms. Online Pharmacies represent a growing segment due to the increasing demand for convenient and discreet purchasing options. With the rise of e-commerce and telemedicine, patients are increasingly turning to online platforms to purchase both OTC and prescription medications for OIC, offering the advantage of home delivery and easier access to treatments. As demand for more convenient healthcare solutions rises, the online pharmacy segment is expected to grow steadily in the coming years.
Global Opioid Induced Constipation Segment Analysis
In this report, the global opioid induced constipation market has been segmented by Drug Class, Prescription Type, End User, and Geography.
Global Opioid Induced Constipation Market, Segmentation by Drug Class
The Global Opioid Induced Constipation Market has been segmented by Drug Class into Mu-opioid Receptor Antagonists, Chloride Channel-2 Activators, and Others.
The Global Opioid Induced Constipation (OIC) Market has undergone segmentation by drug class to cater to diverse therapeutic needs and preferences. One key segment comprises Mu-opioid Receptor Antagonists, which work by blocking the effects of opioids on the gastrointestinal tract, thereby relieving constipation. These antagonists offer a targeted approach to managing OIC while preserving the analgesic effects of opioid medications, enhancing patient comfort and treatment adherence. Another significant segment includes Chloride Channel-2 Activators, which promote fluid secretion into the intestine, softening stool and facilitating bowel movements. This class of drugs provides an alternative mechanism for alleviating OIC and is particularly beneficial for patients who may not respond adequately to mu-opioid receptor antagonists.
The Others segment within the Global OIC Market encompasses a range of emerging and adjunctive therapies aimed at addressing constipation associated with opioid use. This segment may include dietary supplements, laxatives, prokinetic agents, and other supportive treatments that complement pharmacological interventions. By offering a diverse array of treatment options, this segment caters to the individualized needs of patients and allows healthcare providers to tailor therapy based on factors such as severity of constipation, underlying medical conditions, and treatment goals. Additionally, ongoing research and development efforts are focused on identifying novel drug targets and therapeutic modalities within this segment, further expanding the treatment armamentarium for OIC.
The segmentation of the Global OIC Market by drug class reflects the multifaceted nature of constipation management in patients receiving opioid therapy. Each segment offers distinct mechanisms of action and therapeutic benefits, allowing for a comprehensive approach to addressing OIC. By providing healthcare providers with a range of pharmacological and adjunctive options, this segmentation enhances treatment efficacy, patient satisfaction, and overall outcomes in individuals experiencing constipation due to opioid use.
Global Opioid Induced Constipation Market, Segmentation by Prescription Type
The Global Opioid Induced Constipation Market has been segmented by Prescription Type into Over The Counter and Prescription.
The global opioid-induced constipation (OIC) market segmentation by prescription type into over-the-counter (OTC) and prescription reflects the diverse approaches to managing this common side effect of opioid therapy. Over-the-counter medications provide accessible and convenient options for individuals experiencing mild to moderate constipation associated with opioid use. These products typically include laxatives, stool softeners, and fiber supplements, offering symptomatic relief without the need for a prescription. OTC treatments play a crucial role in empowering patients to self-manage their constipation symptoms and can be particularly beneficial for those with occasional or short-term opioid use.
Prescription medications are tailored for individuals with more severe or persistent OIC symptoms that do not respond adequately to OTC interventions. These prescription therapies often target specific mechanisms underlying opioid-induced constipation, such as peripherally acting mu-opioid receptor antagonists (PAMORAs). PAMORAs work by blocking opioid receptors in the gastrointestinal tract, thereby promoting bowel movements while preserving the analgesic effects of opioids. By offering a range of prescription options, healthcare providers can personalize treatment regimens based on the severity of OIC, patient preferences, and underlying medical conditions.
The segmentation of the global OIC market by prescription type reflects the evolving landscape of constipation management and the need for comprehensive approaches to address varying patient needs. While OTC medications provide accessible relief for milder symptoms, prescription therapies offer targeted solutions for individuals with more complex or refractory OIC. Furthermore, ongoing research and development efforts are focused on expanding the repertoire of prescription treatments, including novel drug formulations and combination therapies, to enhance efficacy and patient outcomes in managing this challenging condition.
Global Opioid Induced Constipation Market, Segmentation by End User
The Global Opioid Induced Constipation Market has been segmented by End User into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
The Global Opioid Induced Constipation (OIC) Market is segmented by end-user into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies represent the largest segment in this market, as hospitals are primary settings for patients receiving opioid medications, particularly those undergoing surgery or managing chronic pain. Hospital pharmacies are integral in providing specialized medications to manage opioid-induced constipation, including prescription laxatives, stool softeners, and newer pharmaceutical treatments like peripherally acting mu-opioid receptor antagonists. Hospital pharmacists are well-positioned to monitor and adjust treatments for patients with OIC, ensuring effective symptom management and reducing the risk of complications.
Retail Pharmacies play a significant role in the OIC market by providing easy access to over-the-counter medications and prescription drugs for opioid-induced constipation. With the growing number of people prescribed opioids for pain management, retail pharmacies serve as convenient locations for patients to obtain medications to relieve constipation caused by opioid use. These pharmacies offer a variety of treatments, including stool softeners, laxatives, and newer prescription options, which are increasingly available to address OIC. The segment is driven by patient demand for quick, accessible solutions and the role of pharmacists in guiding patients through appropriate treatment choices.
Online Pharmacies are an emerging segment in the OIC market, driven by the increasing trend of e-commerce and the demand for convenience. Online pharmacies offer patients the ability to order medications from the comfort of their homes, including treatments for opioid-induced constipation. This segment is growing rapidly, as more patients seek discreet and easy access to medications, particularly those managing long-term opioid use for chronic pain. Online pharmacies also provide the advantage of home delivery, which appeals to individuals who may have mobility issues or those who prefer to avoid in-person visits. As the digital health landscape continues to evolve, the online pharmacy segment is expected to play an increasingly important role in managing opioid-induced constipation and expanding access to treatment.
Global Opioid Induced Constipation Market, Segmentation by Geography
In this report, the Global Opioid Induced Constipation Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Opioid Induced Constipation Market Share (%), by Geographical Region, 2024
The global opioid-induced constipation (OIC) market demonstrates varying regional market shares influenced by factors such as healthcare infrastructure, prescription practices, regulatory environments, and patient demographics. North America typically dominates the market share due to the high prevalence of opioid use for pain management in the region. The United States, in particular, holds a significant portion of the market share, driven by the widespread prescription of opioids and the subsequent rise in opioid-induced constipation cases. Additionally, the region's robust healthcare expenditure and advanced research facilities contribute to the development and adoption of OIC treatments.
Europe also commands a notable share of the global OIC market, with countries like Germany, the United Kingdom, and France being key contributors. Similar to North America, Europe faces challenges associated with opioid prescription rates and opioid-related constipation. However, the region benefits from stringent regulatory frameworks that prioritize patient safety and efficacy, driving the demand for approved OIC treatments. Furthermore, increasing awareness among healthcare providers and patients about the management of opioid-induced constipation fuels the market growth across European countries.
Regions such as Asia-Pacific and Latin America exhibit comparatively smaller market shares for OIC treatments. Factors contributing to this include lower prescription rates of opioids, cultural differences in pain management practices, and limited access to healthcare services in certain areas. However, as opioid use gradually increases in these regions, coupled with improving healthcare infrastructure and rising awareness about opioid-related complications, the market share for OIC treatments is expected to expand. Pharmaceutical companies are increasingly targeting these emerging markets, recognizing the potential for growth in addressing unmet medical needs related to opioid-induced constipation.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Opioid Induced Constipation Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Increasing Prescription of Opioid Medications
- Growing Awareness of Opioid-Related Side Effects
-
Regulatory Emphasis on Safer Treatment Options- Regulatory bodies globally are placing a heightened emphasis on the development and approval of safer treatment options for opioid-induced constipation (OIC). As the adverse effects of opioid medications, including constipation, garner increased attention, regulatory agencies are working to ensure that patients have access to effective therapies that mitigate these side effects while maintaining pain management efficacy. This regulatory focus has led to more stringent requirements for the evaluation of OIC treatments during clinical trials, emphasizing safety endpoints alongside measures of efficacy. Additionally, regulatory agencies are advocating for post-marketing surveillance programs to monitor the real-world safety and effectiveness of approved OIC therapies, enabling timely detection and management of any emerging risks.
The regulatory emphasis on safer treatment options for OIC is driving pharmaceutical companies to innovate and develop novel therapeutic approaches. Recognizing the need for medications that specifically target constipation without compromising pain relief, drug developers are investing in the research and development of peripherally acting mu-opioid receptor antagonists (PAMORAs) and other targeted therapies. These agents aim to block the effects of opioids on the gastrointestinal tract while preserving their analgesic effects, offering patients a more favorable risk-benefit profile compared to traditional laxatives or opioid antagonists.
Regulatory agencies are working collaboratively with healthcare providers and patient advocacy groups to raise awareness about OIC and promote the adoption of safer treatment options in clinical practice. By providing guidance and educational resources, regulatory bodies empower clinicians to make informed decisions regarding OIC management, ultimately improving patient outcomes and quality of life. This collaborative effort underscores the importance of regulatory oversight in driving advancements in OIC treatment and ensuring that patients receive safe and effective care in the context of opioid therapy.
Restraints:
- Limited Efficacy of Current Treatment Options
- Concerns about Abuse Potential of Opioid Antagonists
-
Cost Constraints in Healthcare Budgets- Cost constraints in healthcare budgets present a significant challenge in addressing opioid-induced constipation (OIC) within the global market. As healthcare systems grapple with rising expenditures and limited resources, the allocation of funds for OIC management may be constrained, leading to potential barriers in access to effective treatments. The high cost of certain pharmacological agents used to alleviate OIC, such as peripherally acting mu-opioid receptor antagonists (PAMORAs), can strain healthcare budgets, particularly in regions with limited reimbursement coverage or reliance on public healthcare funding. Additionally, the need for ongoing management and monitoring of OIC adds to the overall healthcare expenditure, further exacerbating budgetary constraints.
Cost considerations may influence treatment decisions and access to care for patients experiencing OIC. Healthcare providers may opt for less expensive or generic alternatives, which may not always offer optimal efficacy or tolerability compared to newer, more expensive therapies. Additionally, cost-conscious prescribing practices and formulary restrictions imposed by payers can limit patient access to innovative OIC treatments, potentially compromising treatment outcomes and patient satisfaction. The challenge lies in balancing the imperative to manage healthcare costs with the need to provide comprehensive and effective care for individuals living with OIC.
Cost constraints also present opportunities for stakeholders within the OIC market to innovate and optimize resource utilization. Pharmaceutical companies may explore strategies to reduce the cost of developing and manufacturing OIC therapies, such as streamlining production processes or leveraging economies of scale. Similarly, healthcare providers can implement cost-effective approaches to OIC management, including preventive measures, non-pharmacological interventions, and collaborative care models that maximize the use of available resources while ensuring quality patient care. By addressing cost constraints creatively and collaboratively, stakeholders can work towards improving access to effective OIC treatments within the constraints of healthcare budgets.
Opportunities:
- Development of Novel Pharmacological Agents
- Expansion of Non-Pharmacological Treatment Approaches
-
Collaboration for Comprehensive Patient Care- Collaboration among stakeholders is paramount for achieving comprehensive patient care in the global opioid-induced constipation (OIC) market. This collaboration involves healthcare providers, pharmaceutical companies, regulatory agencies, patient advocacy groups, and other relevant parties working together to address the multifaceted challenges associated with OIC. By fostering partnerships and sharing expertise, stakeholders can develop holistic approaches to OIC management that prioritize patient well-being and treatment outcomes. This collaborative effort ensures that patients receive integrated care that considers both the management of pain and the mitigation of opioid-induced side effects like constipation.
Healthcare providers play a central role in facilitating collaboration for comprehensive patient care in the OIC market. They coordinate with specialists, such as gastroenterologists and pain management experts, to tailor treatment plans that address the unique needs of patients experiencing OIC. Additionally, healthcare providers engage in interdisciplinary teamwork, involving nurses, pharmacists, and allied health professionals, to deliver personalized care and support to individuals affected by OIC. By fostering communication and collaboration within healthcare teams, providers can optimize treatment outcomes and enhance patient satisfaction.
Collaboration in the OIC market extends beyond clinical settings to encompass research, advocacy, and policy development. Pharmaceutical companies collaborate with academic institutions and research organizations to advance the development of novel therapies for OIC and conduct clinical trials to evaluate their safety and efficacy. Regulatory agencies collaborate with stakeholders to establish guidelines and standards for the safe and effective management of OIC, ensuring that patients have access to high-quality care. Additionally, patient advocacy groups play a vital role in raising awareness about OIC, advocating for improved access to treatment options, and empowering patients to actively participate in their care journey. Through collaborative efforts across multiple domains, stakeholders can drive positive change and improve outcomes for patients affected by OIC.
Competitive Landscape Analysis
Key players in Global Opioid Induced Constipation Market include:
- Purdue Pharma
- Takeda Pharmaceutical Company Limited
- AstraZeneca plc
- Salix Pharmaceuticals
- Shionogi & Co., Ltd.
- Mallinckrodt Pharmaceuticals
- Progenics Pharmaceuticals, Inc.
- Shire (now part of Takeda)
- Daiichi Sankyo Company, Limited
- Pfizer Inc.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Prescription Type
- Market Snapshot, By End User
- Market Snapshot, By Region
- Global Opioid Induced Constipation Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Prescription of Opioid Medications
- Growing Awareness of Opioid-Related Side Effects
- Regulatory Emphasis on Safer Treatment Options
- Restraints
- Limited Efficacy of Current Treatment Options
- Concerns about Abuse Potential of Opioid Antagonists
- Cost Constraints in Healthcare Budgets
- Opportunities
- Development of Novel Pharmacological Agents
- Expansion of Non-Pharmacological Treatment Approaches
- Collaboration for Comprehensive Patient Care
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Opioid Induced Constipation Market, By Drug Class, 2021 - 2031 (USD Million)
- Mu-opioid Receptor Antagonists
- Chloride Channel-2 Activators
- Others
- Global Opioid Induced Constipation Market, By Prescription Type, 2021 - 2031 (USD Million)
- Over The Counter
- Prescription
- Global Opioid Induced Constipation Market, By End User, 2021 - 2031 (USD Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Opioid Induced Constipation Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Opioid Induced Constipation Market, By Drug Class, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Purdue Pharma
- Takeda Pharmaceutical Company Limited
- AstraZeneca plc
- Salix Pharmaceuticals
- Shionogi & Co., Ltd.
- Mallinckrodt Pharmaceuticals
- Progenics Pharmaceuticals, Inc.
- Shire (now part of Takeda)
- Daiichi Sankyo Company, Limited
- Pfizer Inc
- Company Profiles
- Analyst Views
- Future Outlook of the Market